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With great interest, we read the article of Sari et al. [1] about
decreasing knee swelling in patients with knee osteoarthritis
using intermittent pneumatic compression (IPC). To our
knowledge, this is the ﬁrst study describing the use of IPC as
a treatment for knee osteoarthritis. *e authors found
signiﬁcant eﬀects on reducing knee swelling. *e topic of
research is relevant as knee osteoarthritis is the most
common chronic joint disorder aﬀecting millions of people
worldwide [2]; however, after reading the article, several
questions regarding the study remain unanswered to us. We
hope the authors can provide us more insight into this study.
Firstly, the title, introduction, results, and discussion
suggest that the authors’ main focus in this study was knee
swelling. In the ﬁrst statement of the introduction, knee
swelling is described as the most common symptom of knee
osteoarthritis; however, the literature generally describes
that knee OA typically involves knee pain, stiﬀness, and loss
of function. While swelling is not uncommon, we re-
spectfully believe this statement may be overstating the
clinical importance of swelling in knee OA. To complicate
matters, in the sample size calculation (Section 2.5 in the
article), knee joint range of motion (ROM) was reported to
be the primary outcome measure—this does not match the
stated aims of the study. To try and clarify this discrepancy,
we looked up the study protocol, which stated that knee
swelling and pain intensity were the primary outcome
measures. Unfortunately, we also noticed that the trial
protocol was registered several years after completion of data
collection (the actual study completion date is June 1, 2012)
and just 5 days before the manuscript was submitted for
publication. We cannot help but wonder if ROM was in fact
once the primary outcome, but this cannot be conﬁrmed
given the very late registration of the trial protocol. *e
purpose of a trial protocol is to ensure research integrity. We
would like to recommend avoiding the inappropriate use of
the protocol registration system for future research.
Secondly, some details about participant characteristics
and dropouts have not been reported in this manuscript. We
noticed that all 9 participants who were lost to follow-up
were in the cold pack group (CP group). It remains unclear
when participants were informed about which group they
were allocated to, so could these 9 dropouts in one group be
related to a lack of allocation concealment? In addition, was
this accounted for in the ﬁnal analyses? If so, how? We
respectfully suggest it would be more appropriate to handle
dropouts using an intention-to-treat analysis (ITT).
According to the CONSORT guidelines on reporting of
RCTs [3], the number of participants in each group should
be analyzed using an ITT analysis. Furthermore, although
the exclusion criteria are well described, the inclusion cri-
teria remain unclear to us. Which deﬁnition of the American
College of Rheumatology criteria (ACR criteria) [4] did the
authors use to include patients? Additionally, the severity of
the osteoarthritis and which knee compartments were in-
volved would be interesting to know.
Finally, we respectfully question the use of measuring
tape to quantify knee joint swelling and the interpretation
of these results. Most outcome measures used in this article
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are widely accepted and validated, such as the Western
Ontario and McMaster Universities Osteoarthritis Index
(WOMAC), dynamometer, goniometer, and Visual Ana-
logue Scale (VAS). But the validation of the measuring tape
remains unclear. We recognize that the authors ac-
knowledged that imaging would have been a better option
but that this was cost-prohibitive and, admittedly, we
cannot oﬀer an alternative, equally aﬀordable clinical
measure for quantifying swelling objectively. Can the au-
thors comment on this outcome measure’s reliability and
have properties such as minimal detectable diﬀerence or
minimal clinically important diﬀerence [5] been estab-
lished in this population? Knowing these values would
make it easier to interpret the results. We note the authors
have relied solely on p values to determine whether
treatment was eﬀective. Current best practices encourage
authors to report eﬀect sizes and uncertainty metrics in
addition to p values [6]. Since the authors found no be-
tween-group diﬀerences in pain or physical function
scores, we question whether reduced knee swelling in these
patients translates into clinically meaningful improvement.
Overall, we encourage the authors to exercise caution in
interpreting the results of this study so as not to overstate
the results of their work.
In conclusion, we would like to thank the authors for
their work. We appreciate the substantial undertaking of
conducting a randomized controlled trial and commend the
authors for seeking novel treatments to address this im-
portant clinical population. We hope our feedback and
subsequent author response will serve to improve the
reader’s interpretation of the current study ﬁndings and
similar research in the future.
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